Dare Bioscience shares rise 11.20% premarket after launching Sildenafil Cream to address female sexual health gap.

Dare Bioscience (DARE) rose 11.20% in premarket trading following announcements that providers in select states can now prescribe its DARE to PLAY Sildenafil Cream, a topical treatment designed to enhance female sexual arousal by increasing genital blood flow. The product, targeting a long-standing gap in women’s sexual health solutions, marks the company’s first step in commercializing its pipeline after years of development. The CEO highlighted the innovation’s potential to address unmet needs, contrasting it with male-focused treatments like Viagra. While the company’s financials remain distressed, the launch represents a strategic milestone, signaling market access progress and potentially attracting investor optimism amid limited competition in its niche.